Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes

Maia Kayal; David Kohler; Jean Frederic Colombel; Marla C. Dubinsky; Ryan C. Ungaro

doi:10.1016/j.cgh.2022.01.033

Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes

Maia Kayal, David Kohler, Jean Frederic Colombel, Marla C. Dubinsky, Ryan C. Ungaro

Research output: Contribution to journal › Short survey › peer-review

Original language	English
Pages (from-to)	541-542.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.cgh.2022.01.033
State	Published - Feb 2023

Access to Document

10.1016/j.cgh.2022.01.033

Cite this

@article{d0e3658c43af48a2b1835e82ba3c13e7,

title = "Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes",

author = "Maia Kayal and David Kohler and Colombel, {Jean Frederic} and Dubinsky, {Marla C.} and Ungaro, {Ryan C.}",

note = "Funding Information: Funding Maia Kayal is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Funding Information: Conflicts of interest These authors disclose the following: Jean Frederic Colombel has served as a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, and Tigenix; and has research grants from AbbVie, Janssen, and Takeda. Marla C. Dubinsky has served as a consultant for Janssen, Takeda, Pfizer, Celgene, and AbbVie; and has research grants from Pfizer and AbbVie. Ryan C. Ungaro has served as an advisory board member or consultant for Janssen, Pfizer, and Takeda; and has research grants from AbbVie, Boehringer Ingelheim, and Pfizer. The remaining authors disclose no conflicts. Funding Maia Kayal is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1).",

year = "2023",

month = feb,

doi = "10.1016/j.cgh.2022.01.033",

language = "English",

volume = "21",

pages = "541--542.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes

AU - Kayal, Maia

AU - Kohler, David

AU - Colombel, Jean Frederic

AU - Dubinsky, Marla C.

AU - Ungaro, Ryan C.

N1 - Funding Information: Funding Maia Kayal is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Funding Information: Conflicts of interest These authors disclose the following: Jean Frederic Colombel has served as a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, and Tigenix; and has research grants from AbbVie, Janssen, and Takeda. Marla C. Dubinsky has served as a consultant for Janssen, Takeda, Pfizer, Celgene, and AbbVie; and has research grants from Pfizer and AbbVie. Ryan C. Ungaro has served as an advisory board member or consultant for Janssen, Pfizer, and Takeda; and has research grants from AbbVie, Boehringer Ingelheim, and Pfizer. The remaining authors disclose no conflicts. Funding Maia Kayal is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1).

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85126854806&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2022.01.033

DO - 10.1016/j.cgh.2022.01.033

M3 - Short survey

C2 - 35123095

AN - SCOPUS:85126854806

SN - 1542-3565

VL - 21

SP - 541-542.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 2

ER -